Eades et al. [16] showed that miR-200a could target Keap1 directly and histone deacetylase (HDAC) inhibitor SAHA (suberanilohydroxamic acid, vorinostat) could induce re-expression of miR-200a in breast cancer cell lines. Here, KEAP1 is linked to breast carcinoma.